Toplum kökenli pnömonili çocuklarda hastalık aktivitesinin değerlendirilmesinde yeni bir biyobelirteç olarak C-reaktif protein (CRP)/ortalama trombosit hacmi (OTH) oranı

Year 2017, Volume: 42 Issue: 3, 451 - 458, 30.09.2017

Eda Çelik Güzel , Çiğdem Fidan Savaş Güzel Cem Paketçi

https://doi.org/10.17826/cutf.323816

Cited By: 3

Abstract

Amaç: Son yıllarda inflamasyon göstergesi olarak değerlendirilen C-reaktif proteinin (CRP)/ortalama trombosit hacmi (OTH) oranı ve beyaz küre sayısı (BKS)/ortalama trombosit hacmi (OTH) oranının toplum kökenli pnömonili (TKP) çocuklarda tanı ve hastalık şiddeti ile ilişkisini araştırmaktır.

Gereç ve Yöntem: Çalışma TKP tanısı alan 3 ay ile 18 yaş arasında 60 hasta ve 30 sağlıklı çocuktan oluşturuldu. Hasta ve kontrol grubunda CRP, BKS, OTH, nötrofil/lenfosit oranı (NLO) değerleri ile birlikte CRP/OTH ve BKS/OTH değerleri incelendi. 

Bulgular: Hasta ve kontrol grubu arasında OTH düzeyleri açısından anlamlı fark saptanmazken, CRP/OTH, BKS/OTH, NLO ve plateletkrit düzeyleri hasta grubunda anlamlı olarak yüksek bulundu. Ciddi pnömonili hasta grubunda (n=27) BKS, NLO, BKS/OTH, CRP/OTH ve CRP düzeyleri hafif-ılımlı pnömonili gruba (n=33) göre anlamlı olarak yüksek saptandı. CRP/OTH ve BKS/OTH oranlarının hastalık belirtilerinin süresiyle arasında pozitif korelasyon gösterildi. Receiver Operating Characteric (ROC) analizinde CRP (Eğri altındaki alan (EAA)=0.801), BKS (EAA=0.761) ve BKS/OTH (EAA=0.731) düzeylerinin TKP’nin tanısında yeterliliği anlamlı bulundu. Ciddi TKP’li hastaların ayrımında ise CRP/OTH (EAA=0.733) ve CRP (EAA=0.708) düzeyleri anlamlı bulundu.

Sonuç: CRP/OTH ve BKS/OTH oranları TKP tanısının değerlendirilmesinde ve CRP/OTH oranı hastalık aktivitesinin belirlenmesinde iyi bir belirteç olabileceğini göstermektedir.

Keywords

Pnömoni, C-reaktif protein, beyaz küre sayısı, ortalama trombosit hacmi, hastalık şiddeti

C-reactive protein (CRP)/mean platelet volume (MPV) ratio as a new biomarker for community-acquired pneumonia in children

Abstract

Purpose: Our aim is to evaluate the relationship between C-reactive protein (CRP)/mean platelet volume (MPV) ratio and white blood cell (WBC)/mean platelet volume (MPV) ratio  and diagnosis and disease severity in children with community-acquired pneumonia (CAP).

Material and Methods: 60 patients with CAP including 33 mild-moderate (Group 1) and 27 severe pneumonia (Group 2) and 30 healthy children were examined for routine blood test. WBC, MPV, neuotrophile/lymhocyte ratio (NLR), CRP, WBC/MPV, CRP/MPV values were recorded on each patient and healthy groups.

Result: CRP/MPV, WBC/MPV, NLR and plateletcrit values were significantly higher in patients group than controls, while MPV value is not correlated between patient and control groups. WBC, NLR, WBC/MPV, CRP/MPV and CRP values were higher in the Group 2 compared to Group 1. CRP/MPV and WBC/MPV were positively correlated with duration of symptoms in the CAP. The area under ROC curve of CRP, WBC and WBC/MPV in diagnosing CAP was significant (0.801, 0.761 and 0.731). Also the area under ROC curve of Group 2 in CRP/MPV and CRP in diagnosing CAP was significant (0.733, 0.708).

Conclusion: CRP/MPV and WBC/MPV ratio may be used a marker in the evaluation of CAP diagnosis and CRP/MPV ratio can be good marker prediction of disease activity.

Keywords

Pneumonia, C-reactive protein, white blood cell, mean platelet volume, disease severity

References

• 1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44: 27-72.
• 2. Garau J, Baquero F, Pérez-Trallero E, Pérez JL, Martín-Sánchez AM, García-Rey C et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect. 2008;14:322–29.
• 3. Polverino E, Torres Marti A. Community-acquired pneumonia. Minerva Anestesiol. 2011;77:196-211.
• 4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
• 5. Juvén T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19:293-8.
• 6. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701-7.
• 7. Bekdas M, Goksugur SB, Sarac EG, Erkocoglu M, Demircioglu F. Neutrophil/lymphocyte and C-reactive protein/mean platelet volume ratios in differentiating between viral and bacterial pneumonias and diagnosing early complications in children. Saudi Med J. 2014;35:442-7.
• 8. Long SS, Pickering LK, Prober CG. Principles and Practice of Pediatric Infectious Diseases. 2nd ed, Philadelphia, Churchill Livingstone, 2003. . 9. Tan TQ, Mason EO Jr, Barson WJ, Wald ER, Schutze GE, Bradley JS et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics. 1998;102:1369-75.
• 10. Yavuzcan A, Cağlar M, Ustün Y, Dilbaz S, Ozdemir I, Yıldız E, et al. Evaluation of mean platelet volume, neutrophil/lymphocyte ratio and platelet/ lymphocyte ratio in advanced stage endometriosis with endometrioma. J Turk Ger Gynecol Assoc. 2013;14:210-5.
• 11. Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab Hematol. 2009;31:277-97.
• 12. Karadag-Oncel E, Ozsurekci Y, Kara A, Karahan S, Cengiz AB, Ceyhan M. The value of mean platelet volume in the determination of community acquired pneumonia in children. Ital J Pediatr. 2013;39:16.
• 13. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7:157-61.
• 14. Cicek G, Açıkgöz SK, Yayla Ç, Kundi H, İleri M. White blood cell count to mean platelet volume ratio: A novel and promising prognostic marker for st-segment elevation myocardial ınfarction. Cardiology J. 2016;23:225-35.
• 15. Bradley JS1, Byington CL, Shah SS, Alverson B, Carter ER, Harrison et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:25-76.
• 16. Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos MA et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64:587-91.
• 17. Virkki R1, Juven T, Rikalainen H, Svedström E, Mertsola J, Ruuskanen O. Differentiation of bacterial and viral pneumonia in children. Thorax. 2002;57:438-41.
• 18. Ayata A, Genç H, Sütçü R. The role of procalcitonin, neopterin and C-reactive protein for diagnosis and monitoring in infectious diseases of childhood. Tıp Araştırmaları Dergisi. 2004;2:11-7.
• 19. Uysal P, Tuncel T, Olmez, Babayiğit A, Karaman O, Uzuner N. The role of mean platelet volume predicting acute exacerbations of cystic fibrosis in children. Ann Thorac Med. 2011;6:227-30.
• 20. Yazici S, Yazici M, Erer B, Calik Y, Ozhan H, Ataoglu S. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010;21:122–5.
• 21. Öztürk ZA, Dag MS, Kuyumcu ME, Cam H, Yesil Y, Yilmaz N et al. Could platelet indices be new biomarkers for inflammatory bowel diseases. Eur Rev Med Pharmacol Sci. 2013;17:334-41.
• 22. Şahin F, Yazar E, Yıldız P. Prominent features of platelet count, plateletcrit, mean platelet volume and platelet distribution width in pulmonary tuberculosis. Multidiscip Respir Med. 2012;7:38.
• 23. Safak S, Uslu AU, Korkmaz S, Turker T, Soner S, Lutfi A. Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis. Afr Health Sci. 2014;14.4:919-24.
• 24. Eser İ, Günay Ş, Sak ZHA, Yalçın F , Kürkçüoğlu İC. Pnömoni hastalığında bir tanı indikatörü olarak ortalama trombosit hacmi. Tıp Araştırmaları Dergisi. 2014;12:12-4.
• 25. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-16.
• 26. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949-52.
• 27. Dehghani MR, Rezaei Y, Taghipour-Sani L. White blood cell count to mean platelet volume ratio as a novel non-invasive marker predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome.Cardiol J. 2015;22.4:437-45.
• 28. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M et al. British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl 2):ii1-23.
• 29. Mani CS, Murray DL. Acute pneumonia and its complications. In Principles and Practice of Pediatric Infectious Diseases, 3rd ed (Eds SS Long, LK Pickering, CG Prober):245-57. Philadelphia, Elsevier, 2008.